Published in Oncology Business Week, January 29th, 2006
The total share capital of the company will be purchased for $210 million cash, subject to debt and working capital adjustment. The transaction is expected to close early in 2006.
Acquisition of Kudos Pharmaceuticals represents an important strategic step for AstraZeneca: strengthening its portfolio of promising cancer treatments from external opportunities and also demonstrating its commitment to discover, develop and bring to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.